(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 September 2006 (21.09.2006)

PCT

(10) International Publication Number
WO 2006/099591 A1

(51) International Patent Classification:
A61K 9/14 (2006.01) *A61K 31/573* (2006.01)
A61K 31/404 (2006.01) *A61K 45/06* (2006.01)

(21) International Application Number:
PCT/US2006/009837

(22) International Filing Date: 16 March 2006 (16.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/662,339 16 March 2005 (16.03.2005) US

(71) Applicant *(for all designated States except US)*: **ELAN PHARMA INTERNATIONAL LIMITED** [IE/IE]; TREASURY BUILDING, LOW GRAND CANAL STREET, Dublin 2 (IE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LIVERSIDGE, Gary** [US/US]; 258 Colwyn Terrace, West Chester, Pennsylvania 19380 (US). **JENKINS, Scott** [US/US]; 1451 Carolina Place, Downington, Pennsylvania 19335 (US). **WERTZ, Christian** [US/US]; 125 Highland Avenue, Lansdale, Pennsylvania 19446 (US). **BOSCH, H.** [US/US]; 237 Rodney Circle, Bryn Mawr, Pennsylvania 19010 (US).

(74) Agents: **SIMKIN, Michele** et al.; FOLEY & LARDNER LLP, Washington Harbour, 3000 K Street, N.w., Suite 500, Washington, District Of Columbia 20007-5143 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** NANOPARTICULATE LEUKOTRIENE RECEPTOR ANTAGONIST/CORTICOSTEROID FORMULATIONS

(57) **Abstract:** Nanoparticulate compositions comprising a corticosteroid and a leukotriene receptor antagonist are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining a leukotriene receptor antagonist with a corticosteroid in particle size ranges of less than 2000 n in a single formulation results in improved efficacy. In addition, patient compliance is enhanced since only one dosage form is needed. Furthermore, local administration of the leukotriene receptor antagonist results in less liver toxicity since the liver will be exposed to lower amounts of drug than happens following oral administration. The drug compositions according to the invention can be formulated into inhalation, nasal, or ocular formulations.

WO 2006/099591 A1